Chemosensitivity of B lymphocytes, obtained from 65 patients with B-cell chronic lymphocytic leukemia (B-CLL), Rai stages 0 through IV, was determined using the MTT assay. The results were expressed by the drug concentration required for 50% inhibition of cell viability The cytotoxicity of chlorambucil (CLB) was compared with that of fludarabine and the DNA topoisomerase I inhibitors, camptothecin, 9-aminocamptothecin, 10.1 l-methylenedioxy-20(S)-camptothecin (10.11-MDC) and 9-amino-l0,llmethylenedioxy-20(S)-campthothecin (9-A-lO.Il-MDC). and topotecan. Considerable heterogeneity in sensitivity t o CLB was observed, with a median ICw of 40.5 pmol/L in untreated patients. B-CLL cells from patients treated with CLB had a significantly higher median ICw of 86.0 pmol/L ( P < .01). Untreated as well as CLB-treated patients were divided into two subsets. For the purpose of this study, B-CLL lymphocytes with an ICso CLB of less than 61.0 p m o l / t were designated as "sensitive," and those with an ICso CLB of 261.0 pmol/L were designated as "resistant." After baseline assays, 15 untreated patients received CLB; after treatment, the ICso increased in B-CLL lymphocytes from 13 of 15 patients. The response t o CLB treatment, determined by its effect on the absolute lymphocyte count and by the Eastern Cooperative Oncology Group clinical criteria, was signifi-
"advertisement" in accordance with 18 cantly better in patients whose lymphocytes had an ICw CLB of less than 61.0 pmol/L before therapy ( P < .01). B-CLL lymphocytes also had a variable degree of sensitivity in vitro t o each of the other drugs. There was significant cross-resistance between CLB and fludarabine ( P < 0.01 1. Whereas only 29% of CLB-resistant B-lymphocyte specimens obtained from individual patients were sensitive t o fludarabine in vitro, 52% and 67% of CLB-resistant lymphocyte samples were sensitive t o 10.11-MDC and 9-A-10,11-MDC, respectively. We have previously reported that p53 gene mutations were associated with aggressive B-CLL and a poor prognosis. B lymphocytes from seven patients with these mutations were resistant t o CLB, and five of six were resistant t o fludarabine. Lymphocytes from four of seven were resistant to 10,11-MDC, and three of four were resistant t o 9-A-10,Il-MDC. This study implies that the MTT assay may be useful in identifying subsets of CLL patients resistant t o conventional chemotherapy. However, definitive conclusions can not be drawn in view of the small number of patients studied prospectively. In addition, these results suggest the potential of camptothecin-based therapy for patients unresponsive t o standard treatment. MTT assay correlated well with the dye exclusion method.* These earlier studies evaluated the efficacy of CLB, as compared with other drugs, and its synergism with interferon.'.' Using the MTT assay, in this report, we present longitudinal studies with patients whose lymphocytes showed varying degrees of sensitivity to CLB. Our results show a concordance between the in vitro response to CLB and the effect of therapy on the patient's clinical and absolute lymphocyte count (ALC) response.
In the present study, we also progide data that compare the cytotoxicity of fludarabine, camptothecin (CPT), and several of its analogs with that of CLB in CLL B lymphocytes. The CPTs are inhibitors of DNA topoisomerase I." Among these drugs, 9-aminocamptothecin (9-AC) and 10,ll -methylenedioxy-20(S)-camptothecin (10,l l-MDC) showed an unprecedented effectiveness against various resistant human cancers carried as xenografts by immunodeficient mice.""3
In phase I1 studies, the analog 7-ethyl-l0-[4-(l-piperidyl)-Ipiperidyll-carbonyloxycamptothecin showed substantial activity against a variety of carcinomas, as well as against nonHodgkin's lymphoma and acute Several CPTs are undergoing preclinical screening, and some are already in clinical trials.13"* We now show that 10,ll-MDC and 9-amino-10, I l-methylenedioxy-20(S)-campthothecin(9-A-10,ll-MDC) are effective in killing B-cell CLL (B-CLL) B lymphocytes in vitro.'"'"
We have previously documented that the presence of mutations in the p53 gene had an adverse effect on the prognosis of CLL2'; the present study reports the correlation between these mutations and chemosensitivity to fludarabine, 10,ll-MDC, and 9-A-IO, 1 Our results indicate that the "IT assay may be a valid predictor of the clinical response to CLB. In addition, the CPTs were found to be more cytotoxic than fludarabine to CLB-resistant B-CLL lymphocytes in vitro.
MATERIALS AND METHODS

Patient population.
A total of 65 patients with B-CLL seen at the New York University Medical Center (New York, NY) were studied. The diagnosis of B-CLL required the demonstration of at least 5 X 103/pL monoclonal B lymphocytes positive for CD5, CD19, and CD20. The disease was staged according to Rai et al."
The patient distribution was as follows: 18 patients, stage 0; 24, stage I; 17, stage II; 5, stage 111; and 1 stage IV. The patients were divided into untreated and treated groups. The untreated group consisted of 43 patients who had never received treatment and 3 patients who had been treated more than 1 year before this study. The treated group consisted of 34 patients, 15 of whom were originally included in the untreated patient group. In addition to earlier CLB treatment with or without prednisone, 9 patients had received cyclophosphamide; 5, fludarabine; 2, etoposide or pentostatin; and single patients received either vincristine, mitoxantrone, or CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Responses were evaluated according to the criteria of the EST 2480 Eastern Cooperative Oncology Group (ECOG) protocol.'.23
Lymphocyte isolation. Heparinized blood was obtained from consenting patients. Mononuclear cells were isolated by centrifugation on Ficoll-Hypaque gradients (PH Pharmacia, Uppsala, Sweden); T lymphocytes were removed by sheep erythrocyte rosette formation, and monocytes were depleted by adherence to Falcon plastic dishes (Fisher, Springfield, NJ). Enrichment of B lymphocytes was assessed by flow cytometry with anti-CD5, anti-CD19, and anti-CD20 antisera. Purity of greater than 95% B-CLL B lymphocytes with fewer than 2% T lymphocytes, as determined by flow cytometry with anti-CD3, was obtained by this procedure.
Tissue culture. A T-cell acute lymphoblastic leukemia line RPMI 8402 and its CPT-K5 subline, which is resistant to CPT-11 I s were obtained from Dr T. Andoh (Aichi Cancer Center Research Institute, Nagoya, Japan) and grown as a cell suspension in RPMI 1640-10% heat-inactivated fetal calf serum at 37°C in 95% air/5% COz. The culture medium contained 100 U/mL penicillin G-sodium, 100 pg/mL streptomycin sulfate, 0.25 pg/mL amphotericin, 2 gm/ L sodium bicarbonate, and 1% L-glutamine (GIBCO, Grand Island, NY).
Drugs. CLB was purchased from Sigma (St Louis, MO), and fludarabine was provided by the Division of Cancer Treatment (National Cancer Institute, Bethesda, MD) and purchased from Berlex Laboratories (Alameda, CA); topotecan was supplied by SmithKline Beecham (King of Prussia, PA). CPT and the analogs 9-AC, 10,ll-MDC, and 9-A-10,ll-MDC were obtained from Dr Monroe C. Wall phosphate-buffered saline) was added for an additional 3 hours. The precipitated MTT formazan was dissolved in 100 pL of isopropanol: 1 N HCl (24:l). After 30 minutes of incubation at 37"C, the A570 was measured on a MultiWell Plate Reader (Dynatech MC 600; Dynatech Laboratories, Inc, Chantilly, M). Viability was expressed as the ratio of A570 drug-treatedcontrol sample. Cells from all patients were studied on multiple occasions, ranging from 4 to 25 times.
Statistical a n a l y s i~.~~.~~ Comparison between patient samples was assessed by Fisher's exact test for nominal variables and by a nonparametric test of serial randomness. P values in all analyses were two-tailed. The SAS system was used for all statistical calculations.
RESULTS
Correlation of MTT assay results with response to CLB
treatment. The drug concentration required for 50% inhibition of cell viability (ICs0) of CLB in B lymphocytes from untreated patients ranged from 7 to 275 pmoVL. The median ICs0 in this group (Fig 1A) was 40.5 p m o n (n = 46), whereas cells from patients who were treated with CLB or with CLB and prednisone (Fig 1B) within 12 months before the "IT assay had a higher median ICs0 value of 86.0 pmol/ L (n = 34; P < .01). In both the treated and untreated groups, the preparation used in the MTT assay contained more than 90% CD5+ B lymphocytes. No correlation was found between ICs0 and Rai stage.
The median ICs0 CLB for the total (treated and untreated) patient group was 61.0 pmol/L (n = 80; the presence of two runs (clumps), one at the low and the other at the high range of ICso values. Based on this analysis, B lymphocytes with ICso CLB less than 61.0 pmol/L were designated as "sensitive," and those with ICs0 CLB 261.0 pmoVL were designated as "resistant" within the context of this study.
Fifteen patients were entered into a prospective study to correlate the pretreatment ICs0 CLB with the decrease in ALC and clinical response. The baseline pretherapy and maximal posttherapy ICs0 values for 15 previously untreated patients were determined (Fig 2) . The median posttherapy ICso was 5 times the median baseline pretreatment value, with an increase in ICs0 of up to 20-fold after therapy. The increase was observed as early as 2 weeks and as late as 3 months after therapy was instituted. With a maximal followup time of 2 years, the ICso remained elevated in 9 of 13 surviving patients. Among the 46 untreated patients on whom serial assays were performed over a 2-year period, we noted 10 instances of fluctuations in ICs0 (data not shown). The effect of therapy on the clinical response and ALC is shown in Table 1 . Eleven patients whose lymphocytes had an ICso less than 61.0 p m o m during baseline studies all had a partial clinical remission and showed a greater than 70% decrease in ALC after therapy. In contrast, of the 4 patients whose lymphocytes had an ICs0 2 61.0 pmoVL, l had no response, 1 had a partial remission, and 2 had disease progression. The difference in partial remissions between the two groups is also significant by Fisher's exact test (P < .009). The difference in ALC decrease between these two groups was significant (P < .001) as determined by a randomized test.
The pattern of response to treatment is illustrated in sequential studies with B lymphocytes in 6 of the patients over a span of 16 to 30 months Fig 3) . Lymphocytes from patients no. 2, 3, 5 , and 7 had ICso CLB values determined immediately pretherapy, which placed them into the sensitive group. During treatment, there was a rapid increase in IC50 concomitant with a decrease in ALC. The change was noted as early as within 1 week (patient no. 2) and as late as 6 months (patient no. 5). Beyond the observation of an increase in ICso, the small number of patients hampers further correlation between therapy and ICso oscillations. Lymphocytes from patients no. 13 and 15 had pretreatment IC5" CLB values that placed them in the resistant group. With therapy these also showed an increase in ICso and a decrease in ALC, but the ALC remained greater than 60 X 103/pL.
Comparison of CLB, jludarabine, and the camptothecins. The chemosensitivity of lymphocytes from treated and untreated patients to fludarabine, lO,ll-MDC, and 9-A-10,ll-MDC is shown (Fig 4) . The selected limits of sensitivity for each drug (Fig 4 [---I) were defined as the mean IC50 plus 2 SD. As with CLB, lymphocytes with an ICso value above these limits were defined as resistant. The ICs0 values for each drug are shown for cells sensitive to CLB (ICso < 61 . O pmoVL) and CLB resistant (ICs0 2 61.0 pmoVL). The ICso for fludarabine ranged from 6 to greater than 100 pmoVL; the ICso for CLB-sensitive was lower than that of the CLBresistant group (Fig 4A; P .01). As for CLB, a nonparametric test of serial randomness applied to pooled data was significantly positive (P < .01) suggesting the presence of two runs with a clustering of lower and higher IC50s.
For 10,ll-MDC (ICs0, 0.10 to greater than 1.0 pmol/L) and 9-A-10,l l-MDC(ICso, 0.03 to greater than 1 . O pmol/L), there were no significant differences (P > .05) between the subsets of CLB-sensitive and CLB-resistant B lymphocytes (Fig 4B and C) , and there was no evidence against randomness of ICso distribution. Among the CLB-sensitive cells, there is a cluster with low ICso values. Clusters were also observed with fludarabine in cells from 23 of 33 patients, as well as with 10,ll-MDC in 17 of 24 patients, and with 9-A-10,ll-MDC in 22 of 23 patients. CLB-resistant lymphocytes from 13 of 23 patients were sensitive to 10,ll-MDC, and 10 of 15 were sensitive to 9-A-10,ll-MDC. In contrast only 7 of 24 CLB-resistant lymphocyte preparations were sensitive to fludarabine.
When compared with 10,l l-MDC and 9-A10, 11-MDC, equitoxic concentrations were generally higher for CPT (N CPT-sensitive and CPT-resistant tissue-culture lines were used as controls for drug sensitivity. The parent RPM1 8402 line was sensitive to 10,ll-MDC and 9-A-10,ll-MDC (Fig  4) , whereas the CPT-K5 subline showed resistance to these drugs.
Relationship of drug resistance to p53 mutations. In an earlier study, we reported the relationship between CLB resistance and p53 gene mutations in B-CLL lymphocytes.*' Chemosensitivity of B lymphocytes to fludarabine and the CPTs was compared with that of CLB and correlated with the presence of p53 mutations. Lymphocytes with these mutations from all 7 patients were resistant to CLB, and 5 of 6 were resistant to fludarabine ( 4 of 7 patients were resistant to 10,11-MDC, and 3 of 4
lymphocytes, 15 of 17 tested were also sensitive to fluwere resistant to 9-A-10,ll-MDC.
darabine, 14 of 17 were sensitive to 10,11-MDC, and 15 Chemosensitivity of B lymphocytes without p53 mutaof 15 were sensitive to 9-A-10,ll-MDC. Among the 20 tions from 39 patients was also analyzed in terms of CLB patients with CLB-resistant lymphocytes, 6 of 18 tested resistance. Among the 19 patients with CLB-sensitive were sensitive to fludarabine, 9 of 16 were sensitive to 10,11-MDC, and 9 of 1 1 were sensitive to 9-A-10, 1 I-MDC.
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DISCUSSION
The MTT assay has been used to predict the response to therapyz9 and to investigate drug resistance in relapsed acute le~kemia.2~. ' O The assay has been less widely applied to the lymphoid malignancies, including CLL.*' In this report, we establish a positive correlation between in vitro chemosensitivity to CLB and a favorable response to treatment in B-CLL. We have also investigated the in vitro cross-resistance of CLB to fludarabine as well as to CPT and its analogs, a new class of anticancer agents. Three findings with CLB emerge from this study. The first is the marked heterogeneity in the in vitro sensitivity to CLB and the other drugs investi- gated. Cells from the majority of untreated patients are sensitive to CLB, whereas cells from about one third of the cases are consistently more resistant to this drug. This may reflect a manifestation of de novo resistance, a common and serious problem in chemotherapy. The second is the positive correlation between the in vitro chemosensitivity of CLL B lymphocytes and the patients' response to CLB treatment. The wellrecognized variable therapeutic efficacy of CLB may be the in vivo counterpart of the heterogeneity in cytotoxicity observed in vitro. Further studies with a larger number of patients will be required to determine if the MTT assay has a predictive value in the treatment of B-CLL.
A third finding documents the effect of therapy on the CLB. When cells from treated patients were compared with cells from patients who had not received CLB, the median IC5O CLB of the former group was significantly higher than the median ICso of the latter. The possibility was considered that the higher IC50 in patients needing treatment merely reflected a more advanced disease stage rather than a consequence of CLB therapy. Contrary to this concept is the lack of correlation between Rai stage and IC50. Further evidence against this interpretation is the relatively rapid increase in ICm CLB observed after therapy that was not noted in untreated patients.
The CLB resistance observed in vitro after treatment occurred in the leukemic CD5+ B lymphocytes. The increase in ICso was not caused by the presence of T cells or monocytes, because T-cell depletion was complete and monocyte contamination was below 1%. Although some of the 15 patients studied prospectively received prednisone as well as CLB, the effect of therapy on IC50 was the same in patients use only.
For personal at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From receiving CLB alone as in those who were also treated with prednisone. The increase in IC50 most likely stems from the killing of sensitive lymphocytes by CLB, with selection of a resistant subpopulation. The increase observed in IC5,, in some cases appears reversible, despite continued therapy. The fluctuations in ICs0 observed in about one fifth of the untreated patients indicate that factors other than CLB therapy can cause changes in drug resistance that are reflected in the ICs0. We think it is not an artifact of the assay. The nature of these factors remains unclear.
In the second part of the study, the in vitro effects of fludarabine and the CPTs were evaluated. The results with fludarabine showed considerable cross-resistance with CLB. A clinical response to fludarabine in CLB-resistant patients is amply documented. In contrast, our findings of crossresistance in vitro is consistent with the clinical observation that fludarabine does not prolong the survival of patients resistant to CLB (and predni~one).~' Our in vitro results differ from those of others who, using another chemosensitivity assay, find no concordance in cross-resistance between CLB and fludarabine. 6 We have previously reported the association between p53 gene mutations and CLB resistance in CLL lymphocytes." The present work shows that resistance to fludarabine and the CPTs also occurs commonly in lymphocytes with a mutated p53 gene.
Our study also reports the effects of CPT and several of its analogs on CLL lymphocytes. Among these agents, all topoisomerase I inhibitors, two analogs, 10,ll-MDC and 9-A-lO,ll-MDC, showed the greatest activity against CLL lymphocytes. The first of these agents introduces a greater number of breaks into CLL lymphocyte DNA than do CPT or 9-AC.32 In addition, when CLL lymphocytes are incubated with IO,ll-MDC, the amount of cell-associated drug is higher and its retention in the lactone form is greater than that observed with CPT or 9-AC.19.33 These differences may not be solely responsible for the greater cytotoxicity of 10,ll-MDC and 9-A-10,ll-MDC. Although it is tempting to suggest that the greater cytotoxicity is caused by the increased number of breaks induced by these compounds in CLL lymphocytes, the underlying mechanisms for cell killing by these agents remains not completely understood.
The extreme S-phase cytotoxicity of CPT has been extensively documented. In the "collision" model, the interaction between the advancing DNA replication fork and the topoisomerase I-CPT-cleavable complex results in a doublestrand DNA break.34 This event, which triggers S-phasespecific cell killing and G2-phase cell cycle arrest, may be responsible for the highly selective killing of the S-phase cells; however, it cannot solely account for the impressive cytotoxicity to quiescent B-CLL lymphocytes, which are largely arrested at the Go to G, phase of the cell cycle. Additional processes may be involved. 34 CLB is an alkylating agent. Fludarabine, a DNA elongation terminator, is a DNA ligase inhibit~r.~' The CPT analogs, 10,ll-MDC and 9-A-10,11 MDC, are DNA topoisomerase I inhibitors. The reason for the occurrence of cross-resistance to these agents that have different mechanisms of action remains unknown. A common explanation may reside in the cell's ability to repair DNA damage caused by chemotherapeutic agents. The increased expression in B-CLL lymphocyte^^^ of the ERCC-1 gene, which is involved in radiation damage repair, supports such an interpretation. Another mechanism may involve the induction of heat-shock proteins recently described in CLL lymphocyte^.^' These proteins that are induced by several cytostatic drugs may be associated with drug re~istance.~'. 39
